Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in
cognitively impaired Multiple Sclerosis (MS) patients. Primary objective was the assessment
of cognition by the Selective Reminding Test (SRT) -a subtest of the brief repeatable battery
(BRB) - after titration of 4 weeks and maintenance of 12 weeks. This double-blind period was
followed by a 52-week open-label treatment phase to assess long-term safety of rivastigmine
patch in these patients.